IMV

Immunovaccine Inc. ("Immunovaccine" or "IMV") (TSX VENTURE:IMV), a clinical
stage vaccine company, presented positive data from clinical and preclinical
vaccine studies, including DPX-Survivac, the company's lead therapeutic cancer
vaccine, this weekend at the American Association for Cancer Research (AACR)
2014 Annual Meeting. In a poster presentation, Immunovaccine highlighted results
demonstrating that metronomic cyclophosphamide (mCPA), an immune modulating
agent, enhanced the immunogenicity of DepoVax(TM)-based vaccines in preclinical
cancer models consistent with previously reported Phase I data showing a similar
enhancement of DPX-Survivac in patients. Importantly, the animal studies
demonstrated the combination therapy's ability to eliminate advanced tumors that
could not be treated with vaccine or mCPA alone. Tumors exposed to the
combination therapy specifically exhibited an increase in T cell activation
markers, suggesting increased immune-mediated anti-tumor activity at the tumor
site with the vaccine/mCPA therapy and further supporting the use of the
combination therapy in clinical trials. 


The addition of anti-PD-1 checkpoint inhibitor to the DepoVax vaccine/mCPA
combination resulted in further enhanced anti-tumor activity, which allowed the
treatment of more advanced tumors. The effective tumor regressions that were
observed could not be achieved without the use of vaccine or the use of
anti-PD-1. 


Checkpoint proteins are known to suppress immune activity and their expression
was increased in tumors under immune attack from the vaccine therapy.
Down-regulating suppressive mechanisms at the tumor level with the use of
checkpoint inhibitors allowed the robust vaccine therapy to cause tumor
regressions in animals, suggesting that the triple combination of vaccine,
cyclophosphamide and anti-PD-1 may be well suited for the treatment of patients
with aggressive tumors who may not otherwise respond to a less aggressive
vaccine therapy. 


"These study results represent strong support for Immunovaccine's belief that
combination immunotherapies will be essential to treat cancer," said Marc
Mansour, chief operating officer of Immunovaccine. "Combining a vaccine with
immune modulators like cyclophosphamide may be most effective in patients with
no evidence of disease and with a high rate of recurrence, while combining
vaccine-based therapies with synergistic checkpoint inhibitors may be
particularly useful for patients with more aggressive disease." 


A second poster presentation related to DPX-Survivac will also be made during
the AACR conference by an Immunovaccine collaborator, Caprion's ImmuneCarta
business unit. This presentation, which will take place on Wednesday, April 9,
will detail immune response results from Immunovaccine's Phase I study of
DPX-Survivac in ovarian cancer patients. Findings demonstrated that treatment
with DPX-Survivac induced durable target T cell responses, with these responses
more robust when DPX-Survivac was combined with cyclophosphamide as an immune
modulator. These results are consistent with the preclinical study results
presented at AACR and provide further support for the potential for combining
DPX-Survivac with complementary immune modulators and immunotherapies. 


Immunovaccine expects a large randomized Phase II trial of DPX-Survivac to be
initiated in 2014 in ovarian cancer. The 250 patient trial will be sponsored and
conducted by Canada's NCIC Clinical Trials Group (NCIC CTG). Additionally,
researchers at the University of Rome will be initiating a Phase l/II trial of
DPX-Survivac in glioblastoma (brain cancer) with the first patient receiving the
vaccine in the first half of 2014. 


About DepoVax(TM)

DepoVax(TM) is a patented formulation that provides controlled and prolonged
exposure of antigens plus adjuvant to the immune system, resulting in a strong,
specific and sustained immune response with the capability for single-dose
effectiveness. The DepoVax platform possesses impressive flexibility, allowing
it to work with a broad range of target antigens in various therapeutic
applications. The technology is also commercially scalable, with potential for
years of stability and ease of use in the clinic.


About DPX-Survivac

DPX-Survivac consists of survivin-based peptide antigens formulated in the
DepoVax(TM) adjuvanting platform. Survivin has been recognized by the National
Cancer Institute (NCI) as a promising tumor-associated antigen (TAA) because of
its therapeutic potential and its cancer specificity. Survivin is broadly
over-expressed in solid tumors and blood cancers including ovarian, breast,
colon and lung cancers, among others. Survivin plays an essential role in
antagonizing apoptosis, supporting tumor-associated angiogenesis, and promoting
resistance to various anti-cancer therapies. Survivin is also a prognostic
factor for many cancers and it is found in a high percentage of cancer patients.


The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T-cell
immune response against cells presenting survivin peptides on HLA class I
molecules. This targeted therapy attempts to use the immune system to actively
search for tumor cells expressing survivin and destroy them. 


About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease
vaccines based on the Company's DepoVax(TM) platform, a patented formulation
that provides controlled and prolonged exposure of antigens and adjuvants to the
immune system. Immunovaccine has advanced two T cell activation therapies for
cancer through Phase I human clinical trials. Lead cancer vaccine therapy,
DPX-Survivac, is expected to enter Phase II clinical studies in 2014, in ovarian
cancer and glioblastoma (brain cancer). The Company is also advancing an
infectious disease pipeline including innovative vaccines for respiratory
syncytial virus (RSV) and anthrax. 


Connect at www.imvaccine.com

This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future, is forward-looking information.
Forward-looking statements are based on the estimates and opinions of management
on the date the statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual results may differ
materially from those set forth in this press release due to risks affecting the
company, including access to capital, the successful completion of clinical
trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release except
as required by law. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Dr. Marc Mansour
Chief Operating Officer
Immunovaccine Inc.
(902) 492-1819
mmansour@imvaccine.com


Tim Brons
Vida Strategic Partners (media)
(415) 675-7402
tbrons@vidasp.com

(TSXV:IMV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024

(TSXV:IMV)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024